New York, NY -- (SBWIRE) -- 10/08/2020 -- The global favipiravir market is expected to witness a substantial CAGR from 2020 to 2030.

To deal with the current situation of COVID-19 pandemic, there are increasing Emergency Use Authorizations (EUAs) granted for drugs, which have shown promising results against COVID- 19. In February 2020, favipiravir was first studied in China for experimental treatment of the emergent COVID-19 pandemic. Owing to the positive results shown by favipiravir, several countries are granting emergency approvals for the treatment of COVID-19 patients showing mild to moderate symptoms. For instance, in June 2020, Glenmark Pharmaceuticals received manufacturing & marketing approval for antiviral drug Favipiravir (brand name FabiFlu) for such treatment in India. It has shown clinical improvements of up to 88% in COVID-19, with a rapid reduction in the viral load in around four days.

Download PDF for Deep Analysis on COVID-19's Impact on "Favipiravir Market" @ https://www.marketindustryreports.com/pdf/377

Favipiravir Market Prominent Players:

Some of the prominent players in the global favipiravir market are FUJIFILM Toyama Chemical Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., HTC "Chemrar", Beximco Pharmaceuticals Ltd., Beacon Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Rameda, Dr. Reddy's Laboratories Ltd., and Strides Pharma Science Limited, among others.

Growth Factors:

Another factor contributing to the growth of the favipiravir market is the accelerated production of the drug to meet the growing demand for the treatment of COVID-19. For instance, in April 2020, FUJIFILM Corporation expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to boost the production of its influenza antiviral drug, Avigan Tablet. In the future, the company is planning to accelerate production up to 300,000 treatment courses by September 2020. Additionally, it is establishing strategic partnerships with domestic and overseas companies to source raw materials and pharmaceutical substances for various manufacturing processes.

Despite, the positive results of favipiravir in the treatment of mild to moderate symptoms of COVID-19, the current lack of regulatory approvals in several regions as well as purchase restrictions are likely to restraint the market growth. Moreover, the extensive research conducted to find better alternatives for favipiravir may also have a negative impact on the favipiravir market.

Segmentaion Based On:

By Application -

1.Influenza and
2.COVID-19

By Distribution Channel -

1.Hospital Pharmacies,
2.Retail Pharmacies,
3.Online

Get Free Customization @ https://www.marketindustryreports.com/free-customization/377

Regional Analysis:

The market growth is likely to accelerate in North America and Europe during the forecast period owing to the increasing cases of COVID- 19 and extensive clinical trials being conducted in these regions. There are extensive clinical trials being conducted in several countries, such as the U.S., Canada, Italy, France, the UK, and others, to evaluate the effectiveness of favipiravir in the treatment of COVID-19. For instance, in May 2020, Appili Therapeutics Inc. announced Health Canada's regulatory clearance for Appili's Phase 2 study evaluating FUJIFILM Toyama Chemical's (FFTC) favipiravir as a preventative measure against COVID-19 outbreaks. The partially-blinded, cluster-randomized placebo-controlled trial was to be conducted on approximately 760 subjects at long-term care facilities in Ontario, Canada.

Research objectives:-

- To study and analyze the global Favipiravir Market consumption (value & volume) by key regions/countries, product type and application, history data.

- To understand the structure of the Favipiravir Market by identifying its various sub-segments.

- Focuses on the key global Favipiravir Market manufacturers, to define, describe and analyze the sales volume, value, market share, market competitive landscape, SWOT analysis, and development plans in the next few years.

- To analyze the Favipiravir Market with respect to individual growth trends, future prospects, and their contribution to the total market.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Table of Contents

1.INTRODUCTION
1.Market Definition
2.Market Ecosystem
1.Market Classification
2.Geographic Scope
3.Years Considered for the Study
1.Historical Years – 2016 & 2017
2.Base Year – 2018
3.Forecasted Years – 2019 to 2030
3.Currency Used for the Study
4.Report Beneficiary List

2.RESEARCH METHODOLOGY
1.Research Framework
2.Data Collection Technique
3.Data Sources
1.Secondary Sources
2.Primary Sources
4.Market Estimation Methodology
1.Bottoms Up Approach
2.Top Down Approach
5.Data Validation and Triangulation
1.Market Forecasting Model
2.Limitations of the Study
3.Assumptions of the Study

3.ABSTRACT OF THE STUDY

4.MARKET DYNAMICS ASSESMENT
1.Overview
2.Drivers
3.Barriers/Challenges
4.Opportunities

Have Anay Query? Inquire Here @ https://www.marketindustryreports.com/inquiry/377

In the end, Favipiravir Market industry report specifics the major regions, market scenarios with the product price, volume, supply, revenue, production, market growth rate, demand, forecast and so on. This report also presents SWOT analysis, investment feasibility analysis, and investment return analysis.

About Market Industry Reports:

Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

Contact Us:

Phone: + 91 8956767535
Email: sales@marketindustryreports.com